Grupo Fleury
Isabella Dâmaris Passos de Souza is an experienced professional currently serving as Líder de produção at Grupo Fleury since March 2020, where responsibilities include planning and supervising production processes and managing team development. Previous experience encompasses roles as a Laboratory Specialist focusing on Molecular Diagnosis and clinical analysis internships with Simile Medicina Diagnóstica and Drogaria da Vovó, contributing to molecular biology techniques and pharmacy operations. Isabella has a strong research background, having worked on a project evaluating cardiotoxicity markers at CNPq. Educational credentials include a Bachelor’s degree in Pharmacy from Universidade Federal de Minas Gerais and an ongoing course in UX/UI Design at EBAC.
This person is not in any teams
This person is not in any offices
Grupo Fleury
1 followers
With almost 100 years, Grupo Fleury is one of the most respected medical and health organizations in Brazil, recognized by the community and public opinion for its technical, medical, service and management excellence. In recent years, it has accelerated its growth towards being an integrated, preventive and hybrid health ecosystem, combining physical and digital offers. With this integrated system, it has increasingly been able to support the physician's clinical conduct in the search for solutions that meet the needs of each patient, while contributing to the sustainability of the system. In addition to diagnostic medicine, it has expanded its activities to the stages of prevention, primary, secondary and tertiary care. With more than 13 thousand employees and 3 thousand doctors, the company is present in the markets of São Paulo, Rio de Janeiro, Rio Grande do Sul, Paraná, Bahia, Pernambuco, Rio Grande do Norte, Maranhão, Espírito Santo and Distrito Federal. The company has established itself as one of the biggest references in best social, economic and environmental practices (Environmental, Social and Governance - ESG). Recently, it was recognized and was included for the second time in the 'Dow Jones Sustainability Index (DJSI)', of the New York Stock Exchange, in the DJSI Emerging Markets portfolio, being the only company in the Health sector in the Americas to be part of of the index.